drugset / Trial / NCT05585632
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
RandomizedParallel-groupTriple-blindPrevention
Summary
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.
Timeline
- Start
- 2022-10-14
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quadrivalent influenza vaccine | Vaccine | — | Intramuscular |
| Subject | mRNA-1045 | Unknown | — | Intramuscular |
| Subject | mRNA-1230 | Unknown | — | Intramuscular |
| Subject | mRNA-1273.214 | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | mRNA-1345 | Messenger RNA (mRNA) | — | Intramuscular |